QNRX News and Press, Quoin Pharmaceuticals Ltd.

Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has Been Engaged Plans for the Opening of Additional International Sites at an Advan...

ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundat...

Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles technology and other approaches will be utilized to optimize the local delivery ...

2024-05-09 10:51:52 ET More on Quoin Pharmaceuticals Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript Quoin Pharmaceuticals GAAP EPS of -$2.08 Quoin stock craters 47% on public offering after rallying in prior session Seeking Alpha’s...

FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late 2025 ASHBURN, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals...

ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quart...

2024-03-14 12:57:03 ET Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Conference Call March 14, 2024, 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Chief Executive Officer Conference Call Participants Nazibur R...

2024-03-13 16:21:32 ET More on Quoin Pharmaceuticals Quoin stock craters 47% on public offering after rallying in prior session Quoin stock soars 60% on FDA update for ichthyosis drug Seeking Alpha’s Quant Rating on Quoin Pharmaceuticals Historical ear...

Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints Eligibility age for enrollment into both studies has been lowered to fourteen...

SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...